Cardium Therapeutics (NYSE:CXM) is a health sciences and regenerative medicine company focused on the acquisition and strategic development of new and innovative bio-medical product opportunities and businesses. The company’s lead commercial product, Excellagen® topical gel for wound care management, recently received FDA clearance for marketing and sale in the United States. Cardium’s lead clinical development product candidate is Generx®, a DNA-based angiogenic biologic intended for the treatment of patients with myocardial ischemia due to coronary artery disease. For more information visit the company’s Web site at www.cardiumthx.com

Marcum offers an extensive range of professional services and a high degree of specialization. In addition to traditional accounting, assurance, and tax, including domestic and international tax planning and preparation, the firm’s professional services include mergers and acquisition planning, family office services, forensic accounting, and litigation support. For more information on Marcum, visit www.marcumllp.com

Let us hear your thoughts below: